Novo Nordisk and Hims & Hers Reach Agreement, Ending Legal Battle Over Weight Loss Drugs A dispute between pharmaceutical giant Novo Nordisk and telehealth provider Hims & Hers Health Inc. …
Tag:
Novo Nordisk
-
-
Novo Nordisk Navigates Obesity Drug Market Challenges with UBT251 Novo Nordisk is facing headwinds in the competitive obesity drug market following a setback with its CagriSema drug and unexpected sales …
-
Generic Wegovy and Ozempic Could Cost as Little as $3 a Month, Expanding Access Generic versions of Novo Nordisk’s blockbuster medications Wegovy and Ozempic could turn into available for as …
-
FDA Issues Warning to Novo Nordisk Over Misleading Ozempic Ad The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk, instructing the company to cease …
-
Long-Term Effects of Ozempic: What You Demand to Understand You may have heard about – or even experienced – the short-term side effects of Ozempic, such as nausea, vomiting, constipation …
-
Novo Nordisk Cuts Prices of Ozempic, Wegovy, and Rybelsus Novo Nordisk announced significant price reductions for its popular GLP-1 medications – Ozempic, Rybelsus, and Wegovy – in an effort to …
-
Novo Nordisk’s UBT251 Shows Promise in Obesity Treatment Following CagriSema Setback Novo Nordisk is seeking a path forward in the competitive obesity drug market following the recent failure of its …
-
Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well when the larger stock markets do not. But it depends on …
-
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren …
-
The Consumerization of Weight Loss: Pills, Apps, and a $150 Billion Market Ask healthcare industry executives about the future of the weight-loss drug market and the analogies are revealing: monthly …